Published by Josh White on 16th September 2024
(Sharecast News) - Cell engineering technology company MaxCyte announced a strategic platform licence agreement with Kamau Therapeutics, a clinical-stage firm specialising in stem cell gene correction therapies, on Monday.
URL: http://www.digitallook.com/dl/news/story/34557015/...